A detailed history of Commonwealth Equity Services, LLC transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 68,930 shares of VYGR stock, worth $394,968. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,930
Previous 77,905 11.52%
Holding current value
$394,968
Previous $616,000 34.58%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$5.77 - $9.27 $51,785 - $83,198
-8,975 Reduced 11.52%
68,930 $403,000
Q2 2024

Jul 31, 2024

BUY
$7.42 - $10.54 $155,449 - $220,812
20,950 Added 36.78%
77,905 $616,000
Q1 2024

Apr 29, 2024

BUY
$7.15 - $10.84 $407,228 - $617,392
56,955 New
56,955 $530,000
Q1 2023

May 11, 2023

SELL
$6.0 - $10.78 $33,000 - $59,290
-5,500 Reduced 23.4%
18,000 $138,000
Q4 2022

Feb 07, 2023

SELL
$4.94 - $6.61 $4,119 - $5,512
-834 Reduced 3.43%
23,500 $143,000
Q2 2022

Jul 19, 2022

BUY
$4.82 - $10.09 $117,289 - $245,530
24,334 New
24,334 $143,000
Q2 2019

Jul 19, 2019

SELL
$19.18 - $27.88 $256,513 - $372,867
-13,374 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$8.0 - $19.66 $6,520 - $16,022
815 Added 6.49%
13,374 $255,000
Q4 2018

Feb 11, 2019

SELL
$8.59 - $18.05 $17,291 - $36,334
-2,013 Reduced 13.81%
12,559 $118,000
Q3 2018

Nov 06, 2018

SELL
$17.11 - $21.74 $29,087 - $36,958
-1,700 Reduced 10.45%
14,572 $275,000
Q2 2018

Jul 31, 2018

BUY
$16.76 - $23.92 $58,660 - $83,720
3,500 Added 27.4%
16,272 $318,000
Q1 2018

May 14, 2018

SELL
$16.16 - $31.31 $177 - $344
-11 Reduced 0.09%
12,772 $239,000
Q4 2017

Feb 12, 2018

BUY
$12.26 - $25.88 $156,719 - $330,824
12,783
12,783 $212,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $221M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.